stocks that match the above criteria are as follows: Johnson & Johnson (NYSE: JNJ ) Novartis AG (NYSE: NVS ) Pfizer (NYSE: PFE ) Merck & Co. (NYSE: MRK ) Johnson & Johnson is the most diversified company in this group as its pharmaceutical
well as its attractive buyout prospects in light of Pfizer 's (NYSE: PFE ) recent attempts to court Astra (which ultimately ..... support my claim that Astra can flourish independent of Pfizer . Thus, I reaffirm my bull thesis since I'm confident
peers with aging drug pipelines, Pfizer (NYSE: PFE ) has been aggressively acquiring ..... investors need to evaluate whether Pfizer can grow without a big acquisition ..... is likely off the table now for Pfizer after the initial $118 Complete
Sept 27 (Reuters) - Pfizer Inc's Xalkori, which treats lung cancer patients with a specific gene mutation, proved effective in shrinking tumors in those with an even rarer form of the disease, according to data presented at a medical meeting on Saturday.
September 26 (Fitch) Fitch Ratings has affirmed Pfizer Inc.'s ( Pfizer 's) ratings, including the 'A+' Issuer Default ..... release. KEY RATING DRIVERS --Fitch forecasts that Pfizer will operate with total debt leverage rangi
drugs are old and well-established with no revenue growth. For instance the most widely prescribed drug is Pfizer 's (NYSE: PFE ) latanoprost (Xalatan) . Xalatan went generic in 2011 and Mylan (NASDAQ: MYL ) is already selling a generic
are under pressure in response to Pfizer 's ( PFE -1.2% ) notification that it ..... impacting formulated drug supply. Pfizer says that it will advise GLYC on ..... exclusive license agreement with Pfizer was signed in October 2011. The
no secret, Merck (NYSE: MRK ) has had a great 2014, running up over 20% YTD and outperforming its key rivals Pfizer (NYSE: PFE ), Johnson & Johnson (NYSE: JNJ ), GlaxoSmithKline (NYSE: GSK ), Novartis (NYSE: NVS ), & Bristol-Myers
Thermo Fisher Scientific (NYSE: TMO ) enters into an agreement with GlaxoSmithKline (NYSE: GSK ) and Pfizer (NYSE: PFE ) to develop a universal next-generation sequencing (NGS) oncology test for solid tumors that will serve as
Pharmaceuticals ( SLXP -0.2% ) which would submarine Allergan's ( AGN +3.7% ) reported acquisition plans as a tactic to thwart Valeant ( VRX +6.9% ). Actavis itself is supposedly a takeover target of Pfizer ( PFE +1% ). Post your comment!